PD-217,014
http://dbpedia.org/resource/PD-217,014 an entity of type: Thing
PD-217,014 is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2). It was developed as a potentially more potent successor to gabapentin and pregabalin, along with several other analogues such as atagabalin and 4-methylpregabalin, but while PD-217,014 produces visceral analgesic effects in animal studies with higher potency and efficacy than gabapentin, it was not developed further for clinical use because of its comparatively more complex synthesis, compared to other related analogues.
rdf:langString
rdf:langString
PD-217,014
xsd:integer
34542372
xsd:integer
1082988024
xsd:integer
10
xsd:integer
444088
xsd:integer
19264101
xsd:integer
17
xsd:integer
-3
xsd:integer
1
xsd:integer
2
xsd:integer
10313401
rdf:langString
C1C[C@@H]2[C@H]1C[C@]CN
xsd:integer
1
rdf:langString
NDDZVQRQVFTNSN-MBTKJCJQSA-N
rdf:langString
K2T93E812G
xsd:integer
175
rdf:langString
PD-217,014 is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2). It was developed as a potentially more potent successor to gabapentin and pregabalin, along with several other analogues such as atagabalin and 4-methylpregabalin, but while PD-217,014 produces visceral analgesic effects in animal studies with higher potency and efficacy than gabapentin, it was not developed further for clinical use because of its comparatively more complex synthesis, compared to other related analogues.
xsd:nonNegativeInteger
2164
xsd:string
444088-20-4
xsd:string
K2T93E812G
xsd:string
10313401